期刊文献+

复方醋酸环丙孕酮与螺内酯干预对非肥胖型多囊卵巢综合征(PCOS)内分泌代谢的影响 被引量:9

Endocrinology and Metabolism Consequences of Ethinyl Estradiol-Cyproterone Acetate (EE-CA) versus Spironolactone (Sp) in Non-obese Women with Polycystic Ovarian Syndrome (PCOS)
原文传递
导出
摘要 目的:比较复方醋酸环丙孕酮和螺内酯治疗以高雄激素血症为主要表现的非肥胖型多囊卵巢综合征(PCOS)的临床疗效和对内分泌代谢的影响。方法:按前瞻性随机对照研究方法选择以高雄激素血症为主要表现的非肥胖型PCOS患者80例,按随机化分组方案分为复方醋酸环丙孕酮(EE-CA)组和螺内酯(Sp)组,每组40例,分别口服相应的药物6个月,比较治疗前、后的体质量指数(BMI)、腰臀比(WHR)、多毛体征、痤疮程度以及卵巢体积,并测定血清卵泡刺激素(FSH)、黄体生成素(LH)、雌二醇(E2)、泌乳素(PRL)、总睾酮(T)、性激素结合球蛋白(SHBG)、硫酸脱氢表雄酮(DHEAS)、空腹血糖(FPG)、空腹胰岛素(FINS)和血脂的水平,记录服药后不良反应。结果:治疗多毛EE-CA和Sp疗效接近(P>0.05);EE-CA组治疗6个月后痤疮评分下降较Sp组作用明显(P<0.05),在缩小卵巢体积方面显著优于Sp(P<0.05),降低血LH、LH/FSH、T、游离雄激素指数(FAI)、DHEAS和升高SHBG的作用较Sp组显著(P<0.05,P<0.01);EE-CA组FINS、甘油三酯(TG)和高密度脂蛋白(HDL)高于Sp组(P<0.05)。结论:本研究用于治疗以高雄激素血症为主要表现的非肥胖型PCOS的药物都是有效的;EE-CA降低高雄激素血症的效果优于Sp,但对高甘油三酯的患者使用要慎重;Sp亦有较好的降雄激素作用,且对糖、脂代谢没有显著影响。 Objective: To evaluate the efficacy and endocrinologic metabolic consequences of ethinyl estradiol-cyproterone acetate(EE-CA) versus spironolactone(Sp) in treating hyperandrogenism of non-obese women with polycystic ovarian syndrome(PCOS).Methods: Eighty non-obese women with PCOS were included in this prospective randomise controlled study.According to randomisation,patients were allocated to receive either EE-CA or Sp for 6 months.Body mass index(BMI),waist-to-hip ratio(WHR),hirsutism,acne degree and ovarian volume,serum samples for hormones,fasting glucose(FPG) and fasting insulin(FINS) levels,sex hormone-binding globulin(SHGB) levels,and lipid profile were measured at baseline,after the third treatment cycle and sixth treatment cycle.The incidence of side effects was recorded.Results: There was no difference in the effect of treating hirsutism between the two groups(P0.05).Compared with Sp,EE-CAdecreased the acne scores significantly after 6 months of treatment(P0.05),and was superior in reducing thesize of the ovary,decreasing the serum LH level,LH/FSH ratio,FAI,DHEAS and increasing the SHBG level(P0.05,P0.01).The FINS,triglyceride and HDL level of EE-CA group were higher than those of Sp group(P0.05).Conclusion: Both EE-CA and Sp are effective in treating hyperandrogenism of non-obese women with PCOS.EE-CA is superior to Sp in improving hyperandrogenism,however,should be cautious to apply to thepatients with high triglyceride;Sp also has good effect on decreasing the T level,and has no significant influence on glucose and lipid metabolism.
作者 常翠芳 王莉
出处 《生殖与避孕》 CAS CSCD 北大核心 2011年第9期607-612,共6页 Reproduction and Contraception
关键词 多囊卵巢综合征(PCOS) 非肥胖型 复方醋酸环丙孕酮(EE-CA) 螺内酯(SP) polycystic ovarian syndrome(PCOS) non-obese ethinyl estradiol-cyproterone acetate(EE-CA) spironolactone(Sp)
  • 相关文献

参考文献13

  • 1Goodarzi MO, Dumesic DA, Chazenbalk G, et al. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol, 2011, 7(4):219-31.
  • 2Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med, 2010, 30(8):41.
  • 3Chen ZJ, Shi Y. Polycystic ovary syndrome. Front Med China, 2010, 4(3):280-4.
  • 4The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod, 2004, 19(1):41-7.
  • 5Robert Y, Dubmlle F, Gaillandre L, et al. Ultrasound assessment of ovarian stroma hypertrophy in hyperandrogenism and ovulation disorders: visual analysis versus computerized quantification. Fertil Steril, 1995, 64(2):307-12.
  • 6Fenkci SM, Fenkci N, Oztekin O, et al. Serum total L-camitine levels in non-obese women with polucystic ovary syndrome. Hum Reprod, 2008, 23(7): 1602-6.
  • 7于传鑫,李诵炫.多囊卵巢综合征.实用妇科内分泌学.第2版,上海:复旦大学出版社,2004:150
  • 8胡敏,王勇,侯丽辉,吴效科.多囊卵巢综合征卵泡膜细胞功能的研究[J].生殖与避孕,2008,28(7):444-447. 被引量:10
  • 9翟晓华,黄晓兰.复方醋酸环丙孕酮联合安体舒通治疗PCOS不孕的疗效观察[J].实用妇产科杂志,2007,23(8):492-494. 被引量:4
  • 10Morin-Papunen L, Vauhkonen I, Koivunen R, et al. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of n nobese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab, 2003, 88(1): 148-56.

二级参考文献24

  • 1刘金勇,刘嘉茵,韩素萍,周伟.丙戊酸钠对卵泡内膜细胞雄激素分泌及相关甾体合成酶改变的影响[J].生殖与避孕,2005,25(11):655-659. 被引量:6
  • 2闫妙娥,宋娟娟,吴效科.PCOS是卵巢对胰岛素超敏的综合征[J].生殖与避孕,2006,26(4):233-236. 被引量:11
  • 3李涌弦,于传鑫.实用妇科内分泌[M].上海:上海医科大学出版社,1997,80
  • 4The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group.Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome[J].Fertil Steril,2004,81(1):19-25.
  • 5Piltonen T,Koivunen R,Rerheentupa A,et al.The enhanced androgen secretion in polycystic ovary syndrome persist the whole erprodution life[J].Abstracts of the 19th Annual Meeting of ESHRE,Medrid Spain,2003,43.
  • 6Loughlin T,Cunningham S,Moore A,et al.Adrenal abnormalities in polycystic ovary syndrome[J].J clin Endocrinil Metab,1986,62(2):142-147.
  • 7Orisaka M, Mizutani T, Tajima K, et al. Effects of ovarian theca cells on granulosa cell differentiation during gonadotropin-independent follicular growth in cattle. Mol Reprod Dev, 2006, 73(6):737-44.
  • 8Yamamoto N, Christenson LK, McAllister JM, et al. Growth differentiation factor-9 inhibits 3', 5'-adenosine monophosphate-stimulated steroidogenesis in human granulosa and theca cells. J Clin Endocrinol Metab, 2002, 87(6): 2 849-56.
  • 9Dooley CA, Atria GR, Rainey WE, et al. Bone morphogenetic protein inhibits ovarian androgen production. J Clin Endocrinol Metab, 2000, 85(9):3 331-7.
  • 10Magoffin DA. Ovarian enzyme activities in women with polycystic ovary syndrome. Fertil Steril, 2006, 86(7):9-11.

共引文献14

同被引文献99

引证文献9

二级引证文献68

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部